Artículos por temáticas

Validation of Parkinson's Disease Ascertainment in the Veterans Administration Electronic Medical Record

Goldman SM, Weaver FM, Cao L, Gonzalez B, Stroupe KT, Colletta K, Jugnundan S, Brown EG, Tanner CM.

Mov Disord. 2025 Feb;40(2):245-253. doi: 10.1002/mds.30075. Epub 2024 Dec 4.

Biology, Pathology, and Targeted Therapy of Exosomal Cargoes in Parkinson's Disease: Advances and Challenges

Almasi F, Abbasloo F, Soltani N, Dehbozorgi M, Moghadam Fard A, Kiani A, Ghasemzadeh N, Mesgari H, Zadeh Hosseingholi E, Payandeh Z, Rahmanpour P.

Mol Neurobiol. 2025 Feb 25. doi: 10.1007/s12035-025-04788-7. Online ahead of print.

Diffusion Kurtosis Imaging in Diagnosing Parkinson's Disease: A Preliminary Comparison Study Between Kurtosis Metric and Radiomic Features

Zhang N, Zhao W, Shang S, Zhang H, Lv X, Chen L, Dou W, Ye J.

Acad Radiol. 2025 Feb;32(2):922-929. doi: 10.1016/j.acra.2024.07.001. Epub 2024 Aug 9.

Advances in hydrogel for diagnosis and treatment for Parkinson's disease

Zhu P, Zhao Z, Gao Y.

Front Pharmacol. 2025 Feb 12;16:1552586. doi: 10.3389/fphar.2025.1552586. eCollection 2025.

A novel alpha-synuclein G14R missense variant is associated with atypical neuropathological features

Brücke C, Al-Azzani M, Ramalingam N, Ramón M, Sousa RL, Buratti F, Zech M, Sicking K, Amaral L, Gelpi E, Chandran A, Agarwal A, Chaves SR, Fernández CO, Dettmer U, Lautenschläger J, Zweckstetter M, Bu

medRxiv [Preprint]. 2025 Feb 7:2024.09.23.24313864. doi: 10.1101/2024.09.23.24313864.

Digital Outcomes as Biomarkers of Disease Progression in Early Parkinson's Disease: A Systematic Review

Rábano-Suárez P, Del Campo N, Benatru I, Moreau C, Desjardins C, Sánchez-Ferro Á, Fabbri M.

Mov Disord. 2025 Feb;40(2):184-203. doi: 10.1002/mds.30056. Epub 2024 Nov 29.

Non-enzymatic posttranslational protein modifications in protein aggregation and neurodegenerative diseases

Baldensperger T, Preissler M, Becker CFW.

RSC Chem Biol. 2024 Dec 19;6(2):129-149. doi: 10.1039/d4cb00221k. eCollection 2025 Feb 5.

Deciphering the role of neuropeptides as biomarkers for early diagnosis of Parkinson's disease

Thakur J, Godad A.

Life Sci. 2025 Feb 15;363:123376. doi: 10.1016/j.lfs.2025.123376. Epub 2025 Jan 8.

Hyperthermia and targeting heat shock proteins: innovative approaches for neurodegenerative disorders and Long COVID

Smadja DM, Abreu MM.

Front Neurosci. 2025 Feb 4;19:1475376. doi: 10.3389/fnins.2025.1475376. eCollection 2025.

Re-examining the pathobiological basis of gait dysfunction in Parkinson's disease

Cho N, Kalia LV, Kalia SK.

Trends Neurosci. 2025 Jan 29:S0166-2236(25)00016-5. doi: 10.1016/j.tins.2025.01.002. Online ahead of print.

Circular RNAs in neurological conditions - computational identification, functional validation, and potential clinical applications

Hatzimanolis O, Sykes AM, Cristino AS.

Mol Psychiatry. 2025 Feb 17. doi: 10.1038/s41380-025-02925-1. Online ahead of print.

Exploring how PRIME-Parkinson care is implemented and whether, how and why it produces change, for who and under what conditions: a protocol for an embedded process evaluation within the PRIME-UK randomised controlled trial

Lloyd K, Tenison E, Smith S, Lithander F, Kidger J, Brant H, Redwood S, Ben-Shlomo Y, Henderson EJ.

BMJ Open. 2025 Feb 2;15(1):e086353. doi: 10.1136/bmjopen-2024-086353.

Correction to 'Still Functional but Limited Postural Adaptation for Individuals with Parkinson's Disease in Goal-Directed Visual Tasks'

Eur J Neurosci. 2025 Feb;61(3):e70012. doi: 10.1111/ejn.70012.

Acyclic sesquiterpenes nerolidol and farnesol: mechanistic insights into their neuroprotective potential

Singh A, Singh L.

Pharmacol Rep. 2025 Feb;77(1):31-42. doi: 10.1007/s43440-024-00672-8. Epub 2024 Oct 22.

"Nattokinase as a potential therapeutic agent for preventing blood-brain barrier dysfunction in neurodegenerative disorders"

Mahakalakar N, Mohariya G, Taksande B, Kotagale N, Umekar M, Vinchurney M.

Brain Res. 2025 Feb 15;1849:149352. doi: 10.1016/j.brainres.2024.149352. Epub 2024 Nov 26.